18F-Labeling and evaluation of novel MDL 100907 derivatives as potential 5-HT2A antagonists for molecular imaging

Nuclear Medicine and Biology

Volumn 37, Issue 4, 2010, Pages 487-495

  Debus, Fabian ^a   Herth, Matthias M ^a   Piel, Markus ^a   Buchholz, Hans Georg ^a   Bausbacher, Nicole ^a   Kramer, Vasko ^a   Lüddens, Hartmut ^a   Rösch, Frank ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

5 HT2A receptor; Fluorine 18; MDL 100907; MH.MZ; PET

Indexed keywords

MDL 105725; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; TRACER; UNCLASSIFIED DRUG; VOLINANSERIN; VOLINANSERIN F 18; DIAGNOSTIC AGENT; FLUORINE; FLUOROBENZENE; PIPERIDINE DERIVATIVE;

ALKYLATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN TISSUE; CEREBELLUM; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; DRUG POTENCY; DRUG PURITY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; FRONTAL CORTEX; IMAGE ANALYSIS; IN VITRO STUDY; ISOTOPE LABELING; MALE; MOLECULAR IMAGING; NEUROIMAGING; NONHUMAN; RADIOCHEMISTRY; RAT; SPRAGUE DAWLEY RAT; STEADY STATE; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY;

ANIMALS; AUTORADIOGRAPHY; FLUORINE RADIOISOTOPES; FLUOROBENZENES; MALE; MOLECULAR IMAGING; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RADIOCHEMISTRY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A;

EID: 77952553317     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.02.002     Document Type: Article

References (20)

1. 18F]altanserin in the human brain. Synapse 1998, 30:380-392.
2. Naughton M., Mulrooney J.B., Leonard B.E. A review of the role of serotonin receptors in psychiatric disorders. Hum Psychopharmacol 2000, 15:397-415.
3. Davis K.L., Charney D., Coyle J.T., Nerneroff C. Neuropsychopharmacology: the fifth generation of progress 2002, Raven Press, New York.
4. Jones B.E., Kryger M.H., Roth T., Dement W.C. Principles and practice of sleep medicine 2000, 134-154. W.B. Saunders Company, Philadelphia.
5. 11C]M100907. Synapse 2000, 38:421-431.
6. 11C]MDL 100,907. JCereb Blood Flow Metab 2000, 20:899-909.
7. 2A receptors with carbon-11-MDL 100,907. J Nucl Med 1998, 39:208-214.
8. 2A receptor. J Labelled Compd Radiopharm 1999, 42:457-467.
9. 18F]MH.MZ. Bioorg Med Chem Lett 2008, 18:1515-1519.
10. 18F]MH.MZ. Nucl Med Biol 2009, 36:447-454.
11. 2A receptor imaging with PET. Bioorg Med Chem 2009, 17:2989-3002.
12. 18F]fluoroethane. Tetrahedron Lett 2003, 44:9165-9167.
13. Lemaire C., Cantineau R., Guillaune M., Plenevaux A., Christiaens L. Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. J Nucl Med 1991, 32:2266-2272.
14. 3H]MDL 100,907. Naunyn-Schmiedeberg's Arch Pharmacol 1997, 356:446-454.
15. 11C]MDL 100907, a radioligand for selective imaging of 5-HT(2A) receptors with positron emission tomography. Life Sci 1996, 58:187-192.
16. 2-like dopamine receptors. Bioorg Med Chem 2007, 15:6819-6829.
17. 2A receptor ligand. Naunyn-Schmiedeberg's Arch Pharmacol 1996, 354:205-209.
18. 2A receptor-mediated responses but does not displace [11C]MDL 100907: small animal PET and gene expression studies. Synapse 2003, 50:251-260.
19. 18F]altanserin: a micro PET study. Brain and Mind Forum 2007, (abstract).
20. 2A receptor antagonist (MDL 100,907) and an active metabolite (MDL 105,725) using in vivo microdialysis sampling in the rat. JPharmaceut Biomed Anal 1998, 17:17-25.